GeneDx Holdings Corp. (WGS) FY2026 YTD Q2 P&L / Income Statement

GeneDx Holdings Corp. (WGS) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (4 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

216,694,000 US dollars

Cost of services

70,245,000 US dollars

Gross profit

146,449,000 US dollars

Operating expenses (calculated)

221,375,000 US dollars

(Loss) income from operations

negative 74,926,000 US dollars

Total non-operating (expense) income, net

negative 5,751,000 US dollars

(Loss) income before income taxes

negative 80,677,000 US dollars

Income tax benefit (expense)

379,000 US dollars

Net (loss) income

negative 81,056,000 US dollars

Other

3,509,000 US dollars

Patients with third-party insurance

179,645,000 US dollars

Institutional customers

32,212,000 US dollars

Self-pay patients

1,328,000 US dollars

Research and development

39,460,000 US dollars

Selling, general and administrative

150,628,000 US dollars

Impairment loss

31,287,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.